Distributor inventory
Voglibose 0.3 mg + Metformin (as Metformin Hydrochloride) 500 mg (SR/ER) per tablet
Type 2 diabetes mellitus (as add-on to diet and exercise) to improve post-meal and overall blood glucose control
Voglibose is an alpha-glucosidase inhibitor that delays carbohydrate digestion and absorption in the intestine, reducing post-meal glucose spikes. Metformin decreases glucose production in the liver and improves insulin sensitivity, helping the body use insulin more effectively.
Take orally exactly as prescribed. Typically taken with meals; voglibose works best when taken at the start of a meal/first bite. Swallow sustained/extended-release tablets whole; do not crush or chew. Follow diet/exercise advice and monitor blood glucose regularly.
Common side effects of STARVOG M 0.3 may include:
Use with caution in kidney disease; metformin is contraindicated in severe renal impairment—dose adjustment/monitoring may be needed. Risk of lactic acidosis increases with renal/hepatic impairment, dehydration, severe infection, hypoxia, and excess alcohol; seek urgent care for fast breathing, severe weakness, abdominal pain, or unusual sleepiness. Temporarily stop metformin around iodinated contrast studies and major surgery as advised by doctor. Use cautiously in liver disease; not recommended in diabetic ketoacidosis. Flatulence/diarrhea may occur initially; maintain hydration.
